4.5 Article

Involvement of LKB1 in epithelial-mesenchymal transition (EMT) of human lung cancer cells

期刊

LUNG CANCER
卷 70, 期 2, 页码 136-145

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2010.02.004

关键词

LKB1; Epithelial-mesenchymal transition; ZEB1; Lung cancer; Invasion

资金

  1. Foundation for Promotion of Cancer Research
  2. Ministry of Health, Labor and Welfare
  3. National Institute of Biomedical Innovation (NiBio)
  4. Grants-in-Aid for Scientific Research [21390075] Funding Source: KAKEN

向作者/读者索取更多资源

Epithelial mesenchymal transition (EMT) is a critical phenotypic alteration of cancer cells that triggers invasion and metastasis. Lung cancer cells often show mesenchymal phenotypes; however, a causative genetic alteration for the induction of EMT in lung cancer cells remains unknown. Recent studies have shown that the LKB1 gene is mutated in up to one-third of lung adenocarcinomas. Therefore, to pursue the possible involvement of LKB1 inactivation in the induction of EMT in lung carcinogenesis, we generated immortalized lung epithelial cells and lung adenocarcinoma cells with stable or transient LKB1 knockdown. LKB1 knockdown increased cell motility and invasiveness, and induced the expression of several mesenchymal marker proteins accompanied by the expression of ZEB1, a transcriptional repressor for E-cadherin and an EMT inducer. In agreement with the recent findings, expression of miR-200a/c was inversely correlated with that of ZEB1 in LKB1 knockdown clones with mesenchymal phenotype. Furthermore, transient knockdown of LKB1 induced ZEB1 mRNA and increased cell motility, and this motility was suppressed by ZEB1 repression. These results strongly indicate that LKB1 inactivation triggers EMT in lung cancer cells through the induction of ZEB1. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Meeting Abstract Oncology

Landscape of Gene Fusions in Lung Adenocarcinoma Patients with Minimal Cigarette Exposure Identified on Malignant Pleural Effusions

M. Saigi, E. Pros, J. Alburquerque Bejar, I. Catala, S. Verdura, R. Palmero Sanchez, M. Jove, E. Nadal, M. Sanchez-Cespedes

JOURNAL OF THORACIC ONCOLOGY (2019)

Meeting Abstract Oncology

DNA-Binding and Gene Expression Profiles in Max Deficient Small Cell Lung Cancer

P. Llabata, M. Torres-Diz, A. Gomez, M. Sanchez-Cespedes

JOURNAL OF THORACIC ONCOLOGY (2019)

Meeting Abstract Oncology

Genetic and Molecular Profiling of Non-Smoking Related Lung Adenocarcinomas

E. Pros, M. Saigi, J. J. Alburquerque Bejar, M. J. Pajares, B. Martinez-Delgado, J. Carretero, R. Tonda, A. Esteve-Codina, S. Verdura, I. Catala, N. Reguart, O. Juan, E. Nadal, E. Felip, L. Montuenga, M. Sanchez-Cespedes

JOURNAL OF THORACIC ONCOLOGY (2019)

Article Oncology

Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors

E. Pros, M. Saigi, D. Alameda, G. Gomez-Mariano, B. Martinez-Delgado, J. J. Alburquerque-Bejar, J. Carretero, R. Tonda, A. Esteve-Codina, I Catala, R. Palmero, M. Jove, C. Lazaro, A. Patino-Garcia, I Gil-Bazo, S. Verdura, A. Teule, J. Torres-Lanzas, D. Sidransky, N. Reguart, R. Pio, O. Juan-Vidal, E. Nadal, E. Felip, L. M. Montuenga, M. Sanchez-Cespedes

ANNALS OF ONCOLOGY (2020)

Article Biochemistry & Molecular Biology

The MNT transcription factor autoregulates its expression and supports proliferation in MYC-associated factor X (MAX)-deficient cells

M. Carmen Lafita-Navarro, Judit Liano-Pons, Andrea Quintanilla, Ignacio Varela, Rosa Blanco, Fabiana Ourique, Gabriel Bretones, Julia Aresti, Ester Molina, Patrick Carroll, Peter Hurlin, Octavio A. Romero, Montse Sanchez-Cespedes, Robert N. Eisenman, M. Dolores Delgado, Javier Leon

JOURNAL OF BIOLOGICAL CHEMISTRY (2020)

Article Oncology

Multi-Omics Analysis Identifies MGA as a Negative Regulator of the MYC Pathway in Lung Adenocarcinoma

Paula Llabata, Yoichiro Mitsuishi, Peter S. Choi, Diana Cai, Joshua M. Francis, Manuel Torres-Diz, Namrata D. Udeshi, Lior Golomb, Zhong Wu, Jin Zhou, Tanya Svinkina, Estrella Aguilera-Jimenez, Yanli Liu, Steven A. Carr, Montse Sanchez-Cespedes, Matthew Meyerson, Xiaoyang Zhang

MOLECULAR CANCER RESEARCH (2020)

Article Oncology

Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer

Joan Frigola, Alejandro Navarro, Caterina Carbonell, Ana Callejo, Patricia Iranzo, Susana Cedres, Alex Martinez-Marti, Nuria Pardo, Nadia Saoudi-Gonzalez, Debora Martinez, Jose Jimenez, Irene Sansano, Francesco M. Mancuso, Paolo Nuciforo, Luis M. Montuenga, Montse Sanchez-Cespedes, Aleix Prat, Ana Vivancos, Enriqueta Felip, Ramon Amat

Summary: Immunotherapy has shown unprecedented long-lasting responses in some patients with advanced non-small cell lung cancer (NSCLC). An integrative analysis of genomic and transcriptomic features of long-term immune checkpoint inhibitors (ICIs)-associated responders revealed an association between TMB and benefit to ICIs. High SCNAs burden correlated with poor response, while PD-L1 expression was increased in patients with long-term response. This study suggests that TMB, SCNAs burden, and PD-L1 are complementary determinants of response to ICIs in NSCLC.

MOLECULAR ONCOLOGY (2021)

Article Oncology

Comprehensive Analysis of SWI/SNF Inactivation in Lung Adenocarcinoma Cell Models

Paola Peinado, Alvaro Andrades, Marta Cuadros, Maria Isabel Rodriguez, Isabel E. Coira, Daniel J. Garcia, Juan Carlos Alvarez-Perez, Carlos Balinas-Gavira, Alberto M. Arenas, Juan Rodrigo Patino-Mercau, Juan Sanjuan-Hidalgo, Octavio A. Romero, Luis M. Montuenga, Julian Carretero, Montserrat Sanchez-Cespedes, Pedro P. Medina

CANCERS (2020)

Article Multidisciplinary Sciences

MAX mutant small-cell lung cancers exhibit impaired activities of MGA-dependent noncanonical polycomb repressive complex

Paula Llabata, Manuel Torres-Diz, Antonio Gomez, Laureano Tomas-Daza, Octavio A. Romero, Joaquim Grego-Bessa, Pere Llinas-Arias, Alfonso Valencia, Manel Esteller, Biola M. Javierre, Xiaoyang Zhang, Montse Sanchez-Cespedes

Summary: MAX mutant SCLCs have either ASCL1 or NEUROD1 or combined characteristics, are MYC independent, and show deficient ncPRC1.6-mediated gene repression.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Article Multidisciplinary Sciences

SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade

Octavio A. Romero, Andrea Vilarrubi, Juan J. Alburquerque-Bejar, Antonio Gomez, Alvaro Andrades, Deborah Trastulli, Eva Pros, Fernando Setien, Sara Verdura, Lourdes Farre, Juan F. Martin-Tejera, Paula Llabata, Ana Oaknin, Maria Saigi, Josep M. Piulats, Xavier Matias-Guiu, Pedro P. Medina, August Vidal, Alberto Villanueva, Montse Sanchez-Cespedes

Summary: This study demonstrates the vulnerability of SMARCA4-deficient tumors to histone demethylases KDM6 inhibitors, highlighting a potential therapeutic strategy for treating cancers with SMARCA4 mutations. The research suggests that SMARCA4-mutant tumors have reduced levels of histone demethylases KDM6s and depend heavily on these demethylases for growth, making them susceptible to inhibition.

NATURE COMMUNICATIONS (2021)

Article Oncology

Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma

Elisabet Aliagas, Ania Alay, Maria Martinez-Iniesta, Miguel Hernandez-Madrigal, David Cordero, Mireia Gausachs, Eva Pros, Maria Saigi, Sara Busacca, Annabel J. Sharkley, Alan Dawson, Ramon Palmero, Jose C. Ruffinelli, Susana Padrones, Samantha Aso, Ignacio Escobar, Ricard Ramos, Roger Llatjos, August Vidal, Eduard Dorca, Mar Varela, Montse Sanchez-Cespedes, Dean Fennell, Cristina Munoz-Pinedo, Alberto Villanueva, Xavi Sole, Ernest Nadal

Summary: The study demonstrates that CDK4/6 inhibitors can reduce proliferation of MPM cells by promoting G1 cell cycle arrest and inducing cell senescence. This suggests the potential of using CDK4/6 inhibitors for the treatment of MPM in clinical settings.

BRITISH JOURNAL OF CANCER (2021)

Review Oncology

Biological and clinical perspectives of the actionable gene fusions and amplifications involving tyrosine kinase receptors in lung cancer

Maria Saigi, Enric Carcereny, Teresa Moran, Marc Cucurull, Ainhoa Hernandez, Eva Pros, Montse Sanchez-Cespedes, Marta Domenech, Anna Martinez-Cardus

Summary: Identifying molecular oncogenic drivers is crucial for precision oncology. Genetic rearrangements, including gene fusions and gene amplification, involving and activating receptor tyrosine kinases (RTKs) are recurrent in solid tumors, particularly in non-small cell lung cancer. Advances in the tools to detect these alterations have deepened our understanding of the underlying biology and tumor characteristics and have prompted the development of novel inhibitors targeting activated RTKs. The review focuses on the genetic and molecular structure of oncogenic RTKs, methods for diagnosis, therapeutic implications of tyrosine kinase inhibitors, and the use of liquid biopsies for monitoring the disease.

CANCER TREATMENT REVIEWS (2022)

Meeting Abstract Oncology

Determinants of immune evasion in MET driven lung cancer

Maria Saigi, Ryohei Yoshida, Erik H. Knelson, Navin R. Mahadevan, Amir Vajdi, Israel Canadas, Tran C. Thai, Mark M. Awad, Montse Sanchez-Cespedes, David A. Barbie

CANCER RESEARCH (2020)

Meeting Abstract Oncology

Searching for genetic alterations that drive the capability of evading tumor immunosurveillance in lung cancer

Juan Jose Alburquerque-Bejar, Maria Saigi, Eva Pros, Octavio Romero, Montse Sanchez-Cespedes

CANCER RESEARCH (2020)

暂无数据